ArticleJAC-antimicrobial resistance2025
Ceftobiprole in cystic fibrosis: a case series.
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF transmembrane conductance ( Objectives: To describe the use of ceftobiprole in the treatment of infective exacerbations in CF. Patients and methods: Ten patients with CF (age 24-63; six male and four female) were treated with ceftobiprole for infective exacerbations following discussion within the multi-disciplinary team. In most patients, ceftobiprole was given concomitantly with other antibiotics. Results: All patients had positive sputum cultures for Conclusions: Ceftobiprole presents a therapeutic option for susceptible infections in CF patients with limited treatment options. Its broad-spectrum coverage may help to reduce polypharmacy. However, further clinical studies are needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.